0.6751
Schlusskurs vom Vortag:
$0.701
Offen:
$0.698
24-Stunden-Volumen:
78,416
Relative Volume:
0.04
Marktkapitalisierung:
$2.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.33M
KGV:
-0.00594
EPS:
-113.7479
Netto-Cashflow:
$-9.12M
1W Leistung:
-3.56%
1M Leistung:
+11.00%
6M Leistung:
-67.70%
1J Leistung:
-86.47%
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Firmenname
Zyversa Therapeutics Inc
Sektor
Branche
Telefon
908-370-5102
Adresse
217 W. MAIN STREET, SOMERVILLE
Vergleichen Sie ZVSA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ZVSA
Zyversa Therapeutics Inc
|
0.6751 | 2.53M | 0 | -21.33M | -9.12M | -113.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Zyversa Therapeutics Inc Aktie (ZVSA) Neueste Nachrichten
ZyVersa progresses with novel inflammation treatment - Investing.com
ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com UK
ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire
ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan
ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
ZyVersa CEO outlines progress in kidney disease drug development - Investing.com
ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks
ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus
ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus
ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus
ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire
ZyVersa Therapeutics appoints new accounting firm - Investing.com
ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia
Virtu Financial LLC Purchases Shares of 25,259 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) - Defense World
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Slashes Annual Losses by 90% While Pushing Forward With Crucial Kidney Disease Drug Trial - Stock Titan
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
ZVSA stock touches 52-week low at $0.69 amid market challenges - Investing.com Australia
ZVSA stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World
ZyVersa’s IC 100 shows promise in OAC treatment study By Investing.com - Investing.com Australia
ZyVersa’s IC 100 shows promise in OAC treatment study - Investing.com India
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ... - The Bakersfield Californian
ZyVersa Therapeutics Highlights Data Published in the - GlobeNewswire
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - TradingView
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on Monday - Defense World
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6% - Defense World
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline - Investing.com Australia
ZVSA stock touches 52-week low at $0.8 amid sharp annual decline By Investing.com - Investing.com South Africa
ZyVersa’s Alzheimer’s treatment shows promise in studies By Investing.com - Investing.com Australia
ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition - TipRanks
ZyVersa’s Alzheimer’s treatment shows promise in studies - Investing.com India
ZyVersa Therapeutics Highlights Data Demonstrating - GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model - The Manila Times
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model - GlobeNewswire
ZyVersa secures $2 million in funding for drug development By Investing.com - Investing.com Canada
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market - GlobeNewswire
ZyVersa Therapeutics announces pricing of $2M private placement - MSN
ZyVersa secures $2 million in funding for drug development - Investing.com
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
Healthcare Fund Backs ZyVersa With $2M Investment: Key Terms Revealed - StockTitan
Finanzdaten der Zyversa Therapeutics Inc-Aktie (ZVSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):